Show simple item record

dc.contributor.authorFox, Simon
dc.contributor.authorHaque, LJ
dc.contributor.authorLovibond, AJ
dc.contributor.authorChambers, TJ
dc.date.accessioned2023-02-15T15:39:04Z
dc.date.available2023-02-15T15:39:04Z
dc.date.issued2003-04-01
dc.identifier.issn0022-1767
dc.identifier.issn1550-6606
dc.identifier.urihttp://hdl.handle.net/10026.1/20394
dc.description.abstract

<jats:title>Abstract</jats:title> <jats:p>Osteoclast formation is dependent on the ability of TGF-β to enable receptor activator of NF-κB ligand (RANKL)-induced commitment of hemopoietic precursors to the osteoclastic lineage. The mechanism by which TGF-β enables formation is unknown. One possibility is that TGF-β opposes Janus kinase (JAK)/STAT signals generated by inhibitory cytokines such as IFN-β. The JAK/STAT pathway is activated by cytokines that induce resistance to osteoclast formation, such as IFN-γ and M-CSF, and the effect of these is opposed by TGF-β. Recently, a group of STAT-induced factors, termed suppressors of cytokine signaling (SOCS), has been identified that inhibit JAK/STAT signals. Therefore, we tested the ability of TGF-β to induce SOCS expression in osteoclast precursors and examined the effect of SOCS expression on osteoclast/macrophage lineage commitment. We found that while SOCS mRNA is undetectable in macrophages, osteoclasts express SOCS-3, and TGF-β up-regulates this expression. Furthermore, TGF-β rapidly induces sustained SOCS-3 expression in macrophage/osteoclast precursors. To determine whether SOCS-3 plays a role in osteoclast differentiation we expressed SOCS-3 in precursors using a retroviral system. We found that osteoclast differentiation was significantly enhanced in SOCS-3-infected precursors, and SOCS-3 expression enables formation in the presence of anti-TGF-β Ab. On the other hand, antisense knockdown of SOCS-3 strongly suppressed osteoclast formation and significantly blunted the response to TGF-β. Moreover, like TGF-β, SOCS-3 expression opposed the inhibitory effect of IFN-β. These data suggest that TGF-β-induced expression of SOCS-3 may represent a mechanism by which TGF-β suppresses inhibitory cytokine signaling, priming precursors for a role in bone resorption.</jats:p>

dc.format.extent3679-3687
dc.format.mediumPrint
dc.languageen
dc.language.isoen
dc.publisherThe American Association of Immunologists
dc.subjectAnimals
dc.subjectBone Marrow Cells
dc.subjectCarrier Proteins
dc.subjectCell Differentiation
dc.subjectCell Lineage
dc.subjectCytokines
dc.subjectGenetic Vectors
dc.subjectGlycoproteins
dc.subjectInterferon-beta
dc.subjectMacrophages
dc.subjectMale
dc.subjectMembrane Glycoproteins
dc.subjectMice
dc.subjectOligodeoxyribonucleotides, Antisense
dc.subjectOsteoclasts
dc.subjectOsteoprotegerin
dc.subjectProtein Biosynthesis
dc.subjectProtein-Tyrosine Kinases
dc.subjectProteins
dc.subjectRANK Ligand
dc.subjectRNA, Messenger
dc.subjectReceptor Activator of Nuclear Factor-kappa B
dc.subjectReceptors, Cytoplasmic and Nuclear
dc.subjectReceptors, Tumor Necrosis Factor
dc.subjectRepressor Proteins
dc.subjectRetroviridae
dc.subjectSignal Transduction
dc.subjectStem Cells
dc.subjectSuppressor of Cytokine Signaling 3 Protein
dc.subjectSuppressor of Cytokine Signaling Proteins
dc.subjectTranscription Factors
dc.subjectTransforming Growth Factor beta
dc.titleThe Possible Role of TGF-β-Induced Suppressors of Cytokine Signaling Expression in Osteoclast/Macrophage Lineage Commitment In Vitro.
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000181754100030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue7
plymouth.volume170 (7)
plymouth.publication-statusPublished
plymouth.journalThe Journal of Immunology
dc.identifier.doi10.4049/jimmunol.170.7.3679
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/School of Biomedical Sciences
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR)
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeUnited States
dc.identifier.eissn1550-6606
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.4049/jimmunol.170.7.3679
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV